Oncology Pharma(OTC) ONPH

Market Cap$1.37M

Since IPO (1992)-100%

5 Year-100%

1 Year+50,000%

1 Month-17%

$0.05

-28.43%

-0.02Today

Oncology Pharma last closing stock price
Metric	Price	Date
Last close	USD 0.05	2026-07-29

Oncology Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-16.57%	USD 0.06	2026-07-22
1 month	-16.5%	USD 0.06	2026-06-29
3 month	-49.9%	USD 0.10	2026-04-30
Year to date	+1,152.5%	USD 0.00	2025-12-31
1 year	+50,000%	USD 0.00	2025-07-29
3 year	-86.82%	USD 0.38	2023-07-28
5 year	-99.77%	USD 22.14	2021-07-30
Since inception	-100%	USD 1,000,000,000.00	1992-05-13

Oncology Pharma Financials at a Glance

Market Cap

$1.37M

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.60M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1212.23 (Low)

Dividend

$0.00

Beta (Volatility)

-1212.23 (Low)

Price

$0.05

Volume

312

Open

$0.05

Price

$0.05

Volume

312

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.05 - $0.36

Estimated Earnings Date

Feb 15, 2004

Dividend

$0.00

Beta (Volatility)

-1212.23 (Low)

Price

$0.05

Volume

312

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.05 - $0.36

Estimated Earnings Date

Feb 15, 2004

ONPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncology Pharma

Oncology Pharma Inc. is a biotechnology company focused on developing, manufacturing, and commercializing therapeutic agents for oncology. The firm is also exploring treatment possibilities for COVID-19 through a collaboration with Kalos Therapeutics Inc.

Products and Services

Development of oncology therapeutic agents
Collaborative research on COVID-19 treatments
Manufacturing capabilities for pharmaceutical products

Growth Outlook

Partnership with Kalos Therapeutics may enhance product pipeline
Focus on oncology positions the company in a growing market
Potential for future collaborations to expand therapeutic offerings

Financial Highlights

Recent quarterly net income of -$820 indicates ongoing operational challenges
Trailing twelve months (TTM) P/E ratio stands at 501, reflecting high investor expectations
Market capitalization of approximately $1.37 million suggests room for growth

Oncology Pharma Inc. has a unique position in the biotechnology sector, particularly in oncology. The company's collaboration with Kalos Therapeutics Inc. opens avenues for innovative treatments, especially in the context of COVID-19. Despite facing operational losses, the high P/E ratio indicates that investors may have optimistic expectations for future growth. The current market capitalization suggests that there is potential for significant appreciation as the company continues to develop its product pipeline and explore new partnerships.

AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

CEO

George Malesek

Website

www.SourcingLink.net

Headquarters

San Francisco, CA 94104, US

ONPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1.08%

Return on Capital

-0.30%

Return on Assets

-0.27%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.37M

Shares Outstanding

27.39M

Volume

312

Avg. Volume

24.16K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$100.94K

EBITDA

-$100.94K

Operating Cash Flow

-$69.37K

Capital Expenditure

$0.00

Free Cash Flow

-$69.37K

Cash & ST Invst.

$398.00

Total Debt

$777.62K

Oncology Pharma Performance Analysis

Oncology Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-03-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Oncology Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-06-30	N/A
Q2	2022-09-30	N/A
Q3	2022-12-31	N/A
Q3	2025-12-31	N/A

Oncology Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-03-31	USD -3.42	N/A
2025	2025-12-31	USD -0.00	-100.0%

Oncology Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-06-30	N/A
Q2	2022-09-30	-21328.6%
Q3	2022-12-31	95.6%
Q3	2025-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.37M

N/A

Market Cap/Employee

$1.37M

N/A

Employees

N/A

Net Income

-$820.00

+99.0%

EBITDA

-$820.00

+99.0%

Quarterly Fundamentals

Name

Q3 2025YOY CHG

Total Cash

$398.00

-80.1%

Total Debt

$777.62K

+362.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$777.62K

+362.9%

Return on Assets

-0.27%

N/A

Return on Invested Capital

-0.47%

N/A

Free Cash Flow

-$1.98K

-98.4%

Operating Cash Flow

-$1.98K

-98.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AMPEAmpio Pharmaceuticals, Inc.

AMPEAmpio Pharmaceuticals, Inc.$0.18+0.00%

WUHNWuhan General Group (China), Inc.

WUHNWuhan General Group (China), Inc.$0.00+0.00%

BTTXBetter Therapeutics, Inc.

BTTXBetter Therapeutics, Inc.$0.00+0.00%

PANCPanacos Pharmaceuticals, Inc.

PANCPanacos Pharmaceuticals, Inc.$0.00+0.00%

ARNIArno Therapeutics, Inc.

ARNIArno Therapeutics, Inc.$0.00+0.00%

IVBTInnovation1 Biotech Inc.

IVBTInnovation1 Biotech Inc.$0.00+0.00%

BXRXQBaudax Bio, Inc.

BXRXQBaudax Bio, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About ONPH

What is the current price of Oncology Pharma?

Oncology Pharma is trading at $0.05 per share.

What is the 52-week range for Oncology Pharma?

Over the past 52 weeks, Oncology Pharma has traded between $0.05 and $0.36.

How much debt does Oncology Pharma have?

As of the most recent reporting period, Oncology Pharma reported total debt of $0.00.

How much cash does Oncology Pharma have on hand?

Oncology Pharma reported $42.01K in cash and cash equivalents in its most recent financial results.

What is Oncology Pharma’s dividend yield?

Oncology Pharma does not currently have a dividend yield.

Oncology Pharma(OTC) ONPH

Oncology Pharma Financials at a Glance

ONPH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Oncology Pharma

ONPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Oncology Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ONPH

What is the current price of Oncology Pharma?

What is the 52-week range for Oncology Pharma?

How much debt does Oncology Pharma have?

How much cash does Oncology Pharma have on hand?

What is Oncology Pharma’s dividend yield?

Premium Investing Services